Verastem, Inc. VSTM

Verastem Oncology announced that abstracts from the Phase 2 RAMP 201 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC) were selected for IGCS 2026: a late-breaking oral presentation on molecular profiling and tumor biomarker analysis from RAMP 201, and a seminal oral presentation for RAMP 201J in Japanese patients. An external-control-arm analysis comparing avutometinib+defactinib to standard-of-care in LGSOC will be shown during Poster Rounds. IGCS Global Meeting is October 1-3, 2026 in Montreal. Verastem also references FDA approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC in May 2025 and ongoing efforts in RAMP 301 and RAMP 205. The release contains forward-looking statements and safety information. IGCS presentations and external control data could materially affect investor sentiment and future development of avutometinib+defactinib in LGSOC.

Verastem outlined commercial and clinical priorities at an H.C. Wainwright event. It is commercializing the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and expanding outreach to community oncology practices ahead of the confirmatory Phase III RAMP 301, which is fully enrolled and expected to read out next year with potential expansion into KRAS wild-type disease. VS-7375, a KRAS G12D inhibitor, is in Phase II across pancreatic, non-small cell lung, and colorectal cancers, with October data releases planned and three frontline Phase III programs targeted in the first half of 2027. A 29-patient pancreatic combo (RAMP 205) of avutametinib and defactinib with gemcitabine/Abraxane yielded a 52% response rate and about one year of overall survival. Verastem emphasizes two platforms: the commercial AVMAPKI FAKZYNJA CO-PACK and the development-stage VS-7375, targeting the RAS/MAPK axis. Multiple major product and trial milestones imply substantial near-term and long-term growth potential.

Verastem stock rose 121% over three months on positive company developments. Stock surge of 121% in three months signals major positive shifts likely to boost future performance and sentiment.

Verastem Oncology will present new clinical data on VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, targeting pancreatic, lung, and colorectal cancers. New data on pipeline asset VS-7375 can materially shift Verastem's valuation and competitive standing in oncology.

Verastem (VSTM) held its Q2 2026 earnings call to report financial results and business updates. Q2 2026 earnings call reveals company performance and strategy affecting market views.

Verastem Inc reported strong revenue rebound in Q2 2026 earnings call along with strategic developments. Strong revenue rebound signals major positive shift in financial trajectory and investor outlook.

Verastem Inc. (VSTM) released Q2 earnings call highlights covering financial results and operational updates. Q2 earnings highlights deliver financial performance data that can shift short-term market sentiment without altering long-term trajectory.

Verastem Oncology released second quarter 2026 financial results and highlighted recent business updates. Quarterly financial results and business updates deliver performance metrics that can shift investor views and valuation.

Verastem Oncology dosed the first patient in its TARGET-D 203 Phase 2 registration-directed trial of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. Dosing first patient in Phase 2 registration-directed trial advances VS-7375 development for colorectal cancer treatment.

Verastem Oncology dosed the first patient in the TARGET-D 202 Phase 2 registration-directed trial of VS-7375 for KRAS G12D-mutated advanced non-small cell lung cancer. Dosing first patient in phase 2 registration-directed trial advances Verastem's lead oncology candidate toward potential approval.

Verastem (VSTM) reported encouraging results from the VS-7375 Phase 1/2 trial. Positive Phase 1/2 data for VS-7375 can drive investor sentiment and advance the drug pipeline.

Verastem, Inc. (VSTM) advances KRAS-targeted combination therapy with potential to treat pancreatic cancer. KRAS-targeted therapy development positions Verastem for major advancements in pancreatic cancer treatment market.

Verastem reports VS-7375 trial data demonstrating anti-tumor activity in advanced solid tumors. Positive early clinical data for VS-7375 strengthens Verastem's oncology pipeline and investor outlook.

Verastem's VS-7375 demonstrates clinical activity with a favorable safety and tolerability profile in the TARGET-D 101 Phase 1/2 trial for patients with advanced KRAS G12D-mutated solid tumors. Positive phase 1/2 data advances Verastem's key KRAS G12D oncology asset and supports future development momentum.

Verastem Oncology announced positive updated results from RAMP 205 trial showing avutometinib plus defactinib with chemotherapy improves outcomes in first-line metastatic pancreatic cancer. Positive RAMP 205 data in pancreatic cancer advances Verastem's lead program and can materially lift valuation and partnering prospects.

Verastem Oncology dosed the first patient in TARGET-D 201 Phase 2 registration-directed trial of VS-7375 oral KRAS G12D (ON/OFF) inhibitor for KRAS G12D-mutated metastatic pancreatic cancer. Dosing first patient in registration-directed Phase 2 advances lead KRAS G12D program in major oncology indication.

Verastem Oncology will host an investor conference call to report updated data and progress on VS-7375 oral KRAS G12D (ON/OFF) inhibitor in the TARGET-D clinical program. Release of fresh clinical data on core KRAS inhibitor candidate can materially shift company valuation and investor interest.

VSTM stock rises after hours after FDA grants Fast Track designation to Verastem's lung cancer drug, with retail investors viewing it as potential next Keytruda. FDA Fast Track speeds regulatory path and raises commercial odds for Verastem's lead oncology program.

Verastem Oncology received U.S. FDA Fast Track Designation for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for treatment of KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer. FDA Fast Track designation accelerates regulatory review and boosts market prospects for Verastem's lead oncology candidate.

Verastem, Inc. (NASDAQ:VSTM) released first-quarter earnings, prompting analysts to share views on performance and outlook. Q1 earnings releases and analyst reactions directly impact biotech stock trajectories through financial updates and sentiment shifts.

Verastem, Inc. (VSTM) released Q1 earnings call highlights detailing financial results, clinical pipeline updates, and strategic priorities. Q1 earnings call highlights cover financial performance and clinical developments that could significantly influence VSTM's market trajectory.

Verastem (VSTM) released Q1 2026 earnings call transcript detailing financial results, clinical updates, and strategic outlook. Q1 2026 earnings transcript discloses financial performance, pipeline advancements, and guidance pivotal to VSTM's future trajectory and investor sentiment.

Verastem, Inc. released its Q1 2026 earnings call summary. Earnings updates may shift near-term investor sentiment and financial outlook without guaranteeing major strategic changes.

Verastem, Inc. (VSTM) reported a Q1 loss and missed revenue estimates. Q1 loss and revenue miss signal weaker-than-expected financial performance, likely pressuring short-term stock price and investor sentiment.

Verastem Oncology reported first quarter 2026 financial results and highlighted recent business updates. Quarterly financial results and business updates moderately influence financial performance and investor sentiment.

Verastem Oncology launched the HCP and Patient Reimagine Campaign to increase awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Campaign launch promotes commercialization of targeted co-pack therapy for niche ovarian cancer, likely driving adoption, sales, and investor sentiment.

Verastem Oncology announced two-year median follow-up data on AVMAPKI + FAKZYNJA combination therapy (avutometinib capsules; defactinib tablets) in recurrent low-grade serous ovarian cancer at the SGO 2026 Annual Meeting on Women’s Cancers. Two-year follow-up data on lead combination therapy for recurrent low-grade serous ovarian cancer at major oncology conference signals pipeline progress likely to enhance investor sentiment and stock trajectory.

Verastem Oncology announces late-breaking and regular abstracts accepted for presentation at the AACR Annual Meeting 2026. Late-breaking abstracts at AACR 2026 signal advancing oncology data presentations, likely sparking significant investor interest and stock momentum for VSTM.

Wall Street analysts forecast 159.31% upside for Verastem (VSTM) stock, questioning if such gains are realistic amid its clinical-stage oncology focus and upcoming milestones. Analyst consensus of 159.31% upside targets moderate market sentiment boost and potential short-term price movement without fundamental changes.

Verastem Oncology (VSTM) held its Q4 2025 earnings call, reporting financial results, operational updates, clinical trial progress, and forward-looking guidance on pipeline developments. Q4 earnings call details financial performance, clinical advancements, and strategic outlook, significantly influencing stock trajectory and investor sentiment.